The following statement will be published in the journal, Food and Chemical Toxicology, alongside a selection of letters to the editors regarding the decision to retract the paper by Séralini et al.(Séralini et al., 2012).

In November 2012, this journal published an article titled “Long term toxicity of a Roundup herbicide and a Roundup-tolerant genetically modified maize,” by Séralini et al.(Séralini et al., 2012). The publication of this article caused quite a stir in the media, as well as in the scientific community. The journal received many letters expressing concerns about the validity of the findings. A careful and time-consuming analysis found that the data were inconclusive, and therefore the conclusions described in the article were unreliable. Accordingly, the article was retracted. Since the public announcement of the retraction, the journal has received many letters to the editor; a selection of these letters will be published, along with this response to those letters. Many of these letters expressed concerns about the decision making process behind this action, particularly what role (if any) current or former Monsanto employees played, whether or not COPE guidelines were followed, and if the journal was also considering retraction of a similar paper by Hammond et al.(Hammond et al., 2004). The answers to these questions are below.

The membership of the editorial board is composed of academic, government, and industrial scientists. Contrary to what has been suggested by some, the appointment of Professor Richard Goodman, University of Nebraska, as an Associate Editor was not influenced by Monsanto or any other party. Members of the editorial board are chosen based on their expertise as scientists. It is the goal of this journal to have a variety of different viewpoints. In this case, as in other cases, I as Editor-in-Chief listened to as wide and diverse a set of expertise as possible. To wit, Professor Goodman, along with all other members of the editorial board was involved in initial discussions of the Séralini paper and the request to view raw data. When the request was made to Dr. Séralini to review the raw data, the journal suggested to Dr. Séralini that all parties involved sign a confidentiality agreement. This confidentiality agreement was designed to protect Dr. Séralini and his data so that it was (A) not viewed by anyone he did not want to view his data and (B) that it would not go beyond the people he agreed would review the raw data. Not initially, but during the process, Dr. Séralini made a direct request that Professor Goodman be excluded, and we at FCT readily and quickly agreed. It is understandable that Dr. Goodman’s involvement, however small, might be cause for concern for some. However, the decision to retract the paper was mine alone, made by me exclusively and not by a vote of the editorial board. Further, when Dr. Séralini asked for Dr. Goodman’s involvement to stop, I agreed, fully and promptly.

The Monsanto Company did write a letter to the editor regarding this article, and it was published along with a number of other letters to the editor (Hammond et al., 2013); neither the company nor any of their scientists put any pressure on the Editor in Chief regarding this matter.

A second concern that has been raised is whether this retraction follows the COPE guidelines. The COPE guidelines were consulted when making this decision. According to the COPE guidelines, “Journal editors should consider retracting a publication if… they have clear evidence that the findings are unreliable, either as a result of misconduct (e.g. data fabrication) or honest error (e.g. miscalculation or experimental error).”(COPE, 2009). The retraction statement could have been clearer, and should have referred to the relevant COPE guidelines. The data are inconclusive, therefore the claim (ie, conclusion) that Roundup Ready maize NK603 and/or the Roundup herbicide have a link to cancer is unreliable. Dr. Séralini deserves the benefit of the doubt that this unreliable conclusion was reached in honest error. The review of the data made it clear that there was no misconduct. However, to be very clear, it is the entire paper, with the claim that there is a definitive link between GMO and cancer that is being retracted. Dr. Séralini has been very vocal that he believes his conclusions are correct. In our analysis, his conclusions cannot be claimed from the data presented in this article.

At this point it is very important to state that the retraction does not reflect or impact the journal’s view on GMOs or associated organizations. Our journal would, in fact, very much welcome the opportunity to review follow-up studies that have a greater sample size, a fine-tuned method, and proper controls. We are also actively searching and recruiting people to provide a balance view on this topic to serve on the editorial board.

Finally, the letters post-retraction have questioned whether an earlier study done by Monsanto received different treatment from our journal. This article was published in 2004, well before I became Editor-in-Chief. However, I take the issue seriously and have reviewed this paper in detail. The Hammond et al. article was a 13 week feeding study performed in rats feed grain from Roundup Ready corn which is tolerant to the herbicide glyphosate (Hammond et al., 2004). The authors reported the following: "Purina TestDiets formulated Roundup Ready corn grain into rodent diets at levels of 11 and 33% (w/w). The responses of rats fed diets containing Roundup Ready corn grain were compared to that of rats fed diets containing non-transgenic grain (controls). All diets were nutritionally balanced and conformed to Purina Mills, Inc. specifications for Certified Lab Diet 5002. There were 400 rats in the study divided into 10 groups of 20 rats/sex/group. Overall health, body weight, food consumption, clinical pathology parameters (hematology, blood chemistry, urinalysis), organ weights, gross and microscopic appearance of tissues were comparable between groups fed diets containing Roundup Ready and control corn grain… This study complements extensive agronomic, compositional and farm animal feeding studies with Roundup Ready corn grain, confirming it is as safe and nutritious as existing commercial corn hybrids.” The authors also stated “The study design was adapted from OECD Guideline No. 408 (1981) and the study was reported to have been conducted in general compliance with OECD Good Laboratory Practice (GLP) guidelines at the Metabolism and Safety Evaluation-Newstead, toxicology laboratory.”

In accordance with OECD Guideline No. 408 (OECD, 2009a), the Hammond et al. study was limited to 90 days following and used 20 rats/sex/group, and was conducted in general compliance with OECD Good Laboratory Practice (GLP) guidelines, as previously stated. The Séralini et al. study ran for two (2) years with only 10 rats/sex/group and was reported to be done in a GLP environment according to OECD guidelines (which guideline is not explicitly stated in the paper). Séralini et al. state that they had “had no reason to settle at first for a carcinogenesis protocol using 50 rats per group,” as recommended in OECD Nos. 451 and 453 (guidelines for Carcinogenicity Studies and Combined Chronic Toxicity/Carcinogenicity Studies, respectively)(OECD, 2009a; OECD, 2009b), and instead seem to have opted for 10 rats/sex/group as recommended by OECD No. 408 (guidelines for Repeated Dose 90-day Oral Toxicity Study in Rodents). While the number of animals used may have been sufficient to reach conclusions regarding oral toxicity, it proved insufficient for conclusions related to the carcinogenicity of the test substances.

In conclusion, FCT has retracted this article because our thorough investigations revealed that its methods were scientifically flawed. The low number of animals, and the strain selected, rendered the conclusions unreliable. No definitive conclusions could be drawn from the inconclusive data. Therefore, in accordance with both the COPE guidelines and the journal policy, it was necessary to take this action of retracting the article.

About ElsevierElsevier is a global information analytics business that helps institutions and professionals advance healthcare, open science, and improve performance for the benefit of humanity. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, more than 35,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX Group, a global provider of information and analytics for professionals and business customers across industries. www.elsevier.com